Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Event Logistics

Bristol-Myers Squibb (BMS) building

BMS’ myeloma treatment accepted for priority review

If approved elotuzumab will be marketed as Empliciti

- PMLiVE

US Senator sets sights on medicine pricing

Intends to stop rises in drug prices for US public

Teva Pharma logo

Teva rolls out first migraine patch in US

Delivers alternative treatment option for migraine sufferers

- PMLiVE

Amgen and Novartis collaborate on Alzheimer’s research

Will work on the development and commercialisation of BACE inhibitors

The vitamin D deficiency: should we act?

Healthcare PR agency Say Communications analyses whether headlines are able to trigger a behavioural change with regards to the vitamin D deficiency issue.

Say Communications

- PMLiVE

Is obesity the new smoking?

Is obesity the new smoking? The healthcare PR team at Say communications analyses the question posed by NHS Chief executive Simon Stevens.

Say Communications

Children, the weight issue and how we deal with this responsibly?

Say Communication, Healthcare PR Agency, looks at how children deal with the weight issue and how we can approach it responsibly.

Say Communications

Longevity but at what price?

Say Communications, healthcare PR agency, analyses the prospect of living to 150 years old, thanks to the anti-ageing biomedical research, and what PR will look like.

Say Communications

- PMLiVE

Novartis bags EU approvals for three ex-GSK drugs

Revolade, Tafinlar and Mekinist all receive regulatory approval

- PMLiVE

Industry files complaint against France’s off-label law

Protests against promotion of Roche's Avastin as cheap eye medication

- PMLiVE

Alnylam predicts big things for its PCSK9 inhibitor ALN-PCS

Genesilencing specialist says its early-stage candidate has blockbuster potential

Sanofi and Google partner on digital health in diabetes

Aimto develop new patient tools by harnessing data and miniaturised tech

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links